The infusion chair reclines. The IV is in. And the clock starts.
Five hours later — after the drive there, the lab draw, the waiting, the drip itself, and the slow, foggy drive home — the day is basically gone. Not to rest. Not to family. To treatment.
Ask people going through chemotherapy what the hardest part is, and many expect the answer to be the cancer. But a new survey suggests something more complicated: for most patients, the treatment itself is nearly as heavy a burden as the disease.
In the survey, 70% of patients said the burden of chemotherapy was almost as much as the burden of the cancer itself.
The survey — called Endometrial Cancer: Patients Raise Their Voices — asked 119 U.S. patients with endometrial cancer who had received at least one round of chemotherapy about their real, day-to-day experience of treatment. Its newest findings were presented on October 26, 2026, at the European Society for Medical Oncology (ESMO) Annual Congress in Madrid (poster 1256P).
The lead author, Dr. Ginger J. Gardner, a gynecologic oncologist at Memorial Sloan Kettering Cancer Center, summed up what patients said:
"Patients are telling us that the impact of chemotherapy extends well beyond treatment itself — it follows them home, cutting into their valuable time, impacting their families, and affecting their daily lives. As providers, it's our job to listen, understand how treatment fits into each patient's life, and treat the whole person, not just the disease."
This post breaks down what those 119 patients reported — the side effects, the lost hours, the feeling of being unprepared — and what patients and caregivers can do with that information, including the questions worth asking before the first infusion ever starts.
What Is "Treatment Burden"?
Doctors have a plain term for everything treatment asks of a patient: treatment burden. It is the total weight of being treated — not just whether the medicine works.
Treatment burden includes:
- Physical effects — fatigue, nausea, hair loss, pain, and the rest of the side-effect list.
- Time — travel, waiting rooms, lab work, infusion hours, pharmacy trips, follow-up scans.
- Mental load — trouble concentrating, forgetfulness, anxiety before each cycle, the work of keeping track of it all.
- Life disruption — missed work, missed family events, plans built around "good days" and "bad days."
- Spillover — the burden that lands on partners, adult children, and friends who become caregivers.
Researchers sometimes divide this into the burden of the illness and the burden of the treatment. We usually assume the illness is the heavy one. This survey says patients experience the treatment itself as nearly the same weight.
Think of it like carrying two suitcases instead of one. Everyone plans for the first suitcase — the cancer. Almost nobody warns you how heavy the second one is.
The Myth: "Side Effects Are Just a List on a Consent Form"
Before chemotherapy starts, every patient gets the list. It is read out loud, printed, and signed: hair loss, nausea, fatigue, low blood counts, infection risk.
Here is the misconception this survey busts: that list is not the experience.
A list says "fatigue." It does not say "too tired to shower standing up." A list says "nausea." It does not say "planning every meal, every car ride, and every family dinner around a stomach that cannot be trusted." A list says "treatment every three weeks." It does not say "five hours per session, and the two days after it lost to the couch."
The consent form describes side effects as events. Patients live them as a schedule, a budget, and a weather system that moves into the whole house.
That gap — between the list and the life — is exactly what this survey measured. And the gap shows up in one of its starkest numbers: 59% of patients said they did not feel prepared for the impact chemotherapy had on their lives. These were not patients who skipped the consent conversation. They were patients who had the list — and still were not ready for the weight.
How the Burden Builds, Piece by Piece
The body keeps the score
The physical effects stack on top of each other. In this survey, the most common burdens patients reported were:
- Hair loss — 95%
- Fatigue — 93%
- Nausea and vomiting — 82%
- Trouble concentrating or remembering — 76%
- Muscle soreness and leg cramps — 76%
Read that list slowly. Almost every patient lost hair. Almost every patient was exhausted. Four out of five dealt with nausea or vomiting. Three out of four had "chemo brain" fog or aching, cramping muscles — usually several of these at the same time.
One side effect is a problem to solve. Five at once is a full-time job.
The hours nobody counts
Oncologists talk about "time toxicity" — the time treatment steals. Patients in this survey reported spending an average of 5 hours on a single chemotherapy session, start to finish.
Thirty-seven percent named the time required as a drawback of chemotherapy — more than double the share who said that about other treatment types (13–16%).
And the hours are not neutral. 49% of patients who had one line of chemotherapy said they often felt they were missing out on life because of the time treatment took. Among patients who went through multiple lines, that rose to 69%.
Five hours in a chair is also five hours of not eating normally, not drinking on schedule, and sitting still while your body processes some of the strongest medicines in use. The clock is part of the burden, not separate from it.
The second time is not easier
Many patients assume round two of treatment — a second line of chemotherapy — will be easier because they know what is coming.
The survey says otherwise. Of patients who received multiple lines of chemotherapy, 41% said the second line was worse than the first.
Bodies carry the wear of earlier treatment. Reserves are lower. And the emotional math changes: the first time, hope does a lot of the carrying. The second time, patients know exactly what the five hours, the nausea, and the lost week will feel like — because they have already lived them.
Knowing what is coming does not make the burden lighter. For many patients, it makes it heavier.
The burden lands on the whole household
Cancer treatment is often described as something that happens to one person. Caregivers know better.
About 1 in 5 patients who had a caregiver (21%) named the burden on their caregiver as one of the biggest drawbacks of chemotherapy. Patients watch the people they love absorb the driving, the scheduling, the meal prep, the middle-of-the-night worry — and many carry guilt about it on top of everything else.
When treatment burden rises, it rises for the whole household.
Why This Burden Matters in Real Life
It would be a mistake to read these numbers as complaints. They are clinical facts with clinical consequences.
- People consider stopping. When treatment feels unbearable, patients skip doses, delay cycles, or quietly decide they cannot do another round — sometimes without telling their team why.
- Decisions get made under exhaustion. Consent conversations, second opinions, and trial decisions all land on people who are fatigued, foggy, and nauseated.
- Small problems compound. Nausea leads to skipped meals. Skipped meals lead to dehydration and lost electrolytes. Dehydration deepens fatigue. Fatigue kills activity, and inactivity wastes muscle. The burden is a chain, not a list.
- The unprepared suffer most. A patient who expects the fog, the cramps, and the five-hour days can plan around them. A patient blindsided by them spends the same energy just being shocked.
There is also a fairness point buried in this survey. Endometrial cancer is the most common cancer of the uterus — an estimated 68,000-plus new uterine cancer cases in the U.S. in 2026 — and its incidence rose about 20% between 2002 and 2022. Yet it remains underfunded relative to how many lives it takes. The patients in this survey are part of a large, growing group whose day-to-day experience of treatment has not always been asked about. This survey asked.
What Did the New Survey Find?
The survey's full name is the Endometrial Cancer Patient Experience Survey, and its poster at ESMO 2026 was titled Endometrial Cancer: Patients Raise Their Voices.
The basics:
- Who: 119 U.S. patients with endometrial (uterine) cancer, all of whom had received at least one line of chemotherapy.
- How: an online survey run by The Harris Poll for Eisai Inc., working with patient groups ECANA, FORCE, and the Foundation for Women's Cancer.
- When: patients answered between April and July 2025. Earlier findings were shared at the Society of Gynecologic Oncology meeting in spring 2026; the newest findings were presented at ESMO on October 26, 2026.
- Who they were: median age 59; 93% had also had surgery, 85% radiation, and half had received immunotherapy. About 54% had been through more than one line of chemotherapy.
- The honest fine print: 119 people is a modest sample (results carry a margin of about ±9 percentage points), and some subgroups are small — the researchers themselves flag those numbers as directional, a signal rather than a precise measurement.
With that framing, here is what patients reported.
Finding 1: Treatment burden nearly equals disease burden
70% of patients said the burden of chemotherapy was almost as much as the burden of the cancer itself.
This is the headline, and it deserves a pause. A cancer diagnosis is one of the heaviest things a person can carry. Seven in ten patients said the treatment piled on nearly the same weight again.
It does not mean chemotherapy is a mistake — chemotherapy remains a standard, important part of endometrial cancer care. It means the cost side of the ledger is far bigger than the consent form suggests, and patients are asking for it to be counted honestly.
Finding 2: The side-effect stack is tall — and it stacks
The most commonly reported burdens were hair loss (95%), fatigue (93%), nausea and vomiting (82%), trouble concentrating or remembering (76%), and muscle soreness or leg cramps (76%).
Translate those percentages into a room of 100 patients: 95 lose their hair, 93 are deeply fatigued, 82 are nauseated or vomiting, 76 cannot think as clearly as they used to, and 76 are dealing with aching, cramping muscles.
These are not five separate groups. They are largely the same people, carrying several of these at once, for months.
Finding 3: Most patients did not feel prepared
59% of patients said they did not feel prepared for the impact chemotherapy would have on their lives.
Not unprepared for the diagnosis — unprepared for the daily reality of treatment. This is the most fixable finding in the survey. Preparation is information, planning, and honest expectations, and all three can be improved before the first infusion.
Finding 4: Treatment eats time — and time is life
Patients averaged 5 hours per chemotherapy session. Nearly half of patients treated with one line of chemotherapy (49%) said they often felt they were missing out on life because of treatment time; among those with multiple lines, it was 69%.
Time is the one resource patients cannot get back. When 37% of patients name time itself as a drawback of chemotherapy — far more than for other treatment types — they are saying the schedule is part of the suffering.
Finding 5: Most would prefer not to do it again
71% of patients said they would prefer not to receive chemotherapy again in the future. And among those who had been through multiple lines, 41% said the later treatment was worse than the first.
Read carefully: this is not patients rejecting treatment. The same survey found 72% would feel hopeful if they qualified for a treatment that let them avoid chemotherapy. It is patients saying: if there is another road, I want to know about it.
Finding 6: Patients want a voice and a plan built for them
91% of patients wanted to know more about treatment options besides chemotherapy. 92% said they would prefer a treatment plan tailored to them over a one-size-fits-all approach.
And the burden is shared: about 1 in 5 patients with a caregiver (21%) counted the burden on that caregiver among chemotherapy's biggest drawbacks.
The through-line of all six findings is not "chemotherapy is bad." It is: tell us the whole story, count the whole cost, and let us help choose.
"Patients want more information, more personalized care, and more consideration about what treatment options work best for each person's life and priorities." — the survey team's summary of what patients asked for
Why Supportive Care Is the Other Half of Treatment
Here is the hopeful reading of this survey: almost everything patients named is, at least in part, a supportive-care problem — and supportive care is the part of treatment built specifically to lighten the load. We have written before about why cancer treatment is more than fighting the tumor. This survey is what that idea sounds like in patients' own numbers.
Look at the burden list again, through a supportive-care lens:
- Nausea and vomiting (82%). Every episode drains water and electrolytes — sodium, potassium, and magnesium — that the body needs for energy, muscle function, and a steady heartbeat. Anti-nausea medicines are the first line, and they work best when they are planned ahead rather than chased after the fact. Staying ahead on fluids and electrolytes between cycles is the part patients can influence every day.
- Muscle soreness and leg cramps (76%). Cramps are a classic sign that fluid and mineral balance is off. Magnesium and potassium losses — from vomiting, diarrhea, poor intake, and some chemotherapy drugs themselves — make muscles irritable and cramp-prone. Three out of four patients reporting this is a loud signal that electrolyte support belongs in the conversation, not as an afterthought.
- Fatigue (93%). Fatigue has many drivers, but dehydration and under-fueling are two of the most fixable. A patient who cannot keep fluids and calories down will feel every other side effect more deeply.
- Appetite and weight. Nausea, taste changes, and exhaustion quietly shrink how much people eat and drink. That is the on-ramp to the weight and muscle loss we described in our post on cancer cachexia and early weight loss — another reason the daily basics deserve the same seriousness as the infusion itself.
That is the space HuMOLYTE was made for. HuMOLYTE is a medical food for use under medical supervision, designed to support hydration and electrolyte balance — including magnesium, which many standard drinks do not replace — and gut health during cancer treatment. It does not treat cancer, and it does not make chemotherapy easy. What it supports is the daily foundation that makes the hard days more bearable: fluids in, electrolytes replaced, gut supported.
Practical steps that lighten the load during chemotherapy:
- Plan the chair time. Treat the infusion day like a work shift: a real meal before, fluids during, a ride home arranged, and the next day kept deliberately light.
- Front-load fluids and electrolytes on the days before and after each cycle, when nausea and poor appetite are about to peak.
- Track three things daily: how much you drank, how much you ate, and your worst symptom of the day. Patterns you can see are problems your team can fix.
- Report cramps, dizziness, and very low urine output early. They are often fluid-and-electrolyte problems — and they are usually fixable.
- Ask for a "burden review" at each visit. Two minutes on "what is hardest right now?" changes what gets treated.
What Should Patients and Caregivers Watch For?
Call the care team promptly if you notice:
- Vomiting that prevents keeping fluids down for more than a day
- Very little urination, dark urine, dizziness when standing, or a racing heartbeat (signs of dehydration)
- Frequent or severe leg cramps, muscle weakness, or an irregular heartbeat feeling
- Inability to eat enough to hold weight steady, or rapid weight loss between cycles
- Fatigue so heavy that basic daily tasks — showering, dressing, a short walk — become hard
- Trouble thinking clearly that is new, worsening, or frightening
- Fever of 100.4°F (38°C) or higher, or any sign of infection
- A caregiver who is exhausted, overwhelmed, or out of reserve — that counts as a care problem too
Questions to Ask Your Oncology Team
- Based on my chemotherapy plan, which side effects are most likely for me — and which days of each cycle will probably be the hardest?
- What is my anti-nausea plan for the days after treatment, not just during the infusion?
- How much fluid should I aim for each day, and how will we watch my electrolytes — including magnesium and potassium?
- I have heard muscle cramps are common. What should I do when they start, and when should I call about them?
- What can we do ahead of time to protect my appetite and weight during treatment?
- How long will each session actually take, door to door — and can any labs or visits be combined to save trips?
- What supportive-care services are available to me — nutrition, palliative care, social work, financial counseling — and can I be referred now rather than later?
- If this chemotherapy becomes too much, what other options exist for my cancer, including immunotherapy, targeted therapy, hormonal therapy, or clinical trials?
- How will my preferences and my daily life be factored into decisions if we need a second line of treatment?
- Who should my caregiver talk to if the burden at home becomes too much?
Why This Survey Matters
Oncology has become very good at measuring tumors. It is still learning to measure Tuesdays.
A scan can say whether a treatment is shrinking a cancer. It cannot say whether the patient made it to a grandchild's birthday, kept enough strength to cook, or spent the month feeling prepared or ambushed. Those things are not soft extras. In this survey, they are the difference between a treatment patients can sustain and one they dread repeating.
The survey also carries a message of respect in the other direction. Patients did not ask to be spared hard truths. Ninety-two percent asked for the opposite: a plan shaped around their actual lives, with the full cost on the table. That is a workable request — and preparation, honest expectation-setting, and serious supportive care are how a care team answers it.
The Bottom Line
- In a survey of 119 U.S. endometrial cancer patients presented at ESMO on October 26, 2026, 70% said chemotherapy's burden was almost as much as the burden of the cancer itself.
- The most common burdens were hair loss (95%), fatigue (93%), nausea and vomiting (82%), trouble concentrating (76%), and muscle soreness or leg cramps (76%).
- Patients averaged 5 hours per chemotherapy session; up to 69% felt treatment time was costing them life itself.
- 59% did not feel prepared for chemotherapy's impact — the most fixable finding in the survey.
- 71% would prefer not to receive chemotherapy again, while 91–92% asked for more information about options and for plans tailored to their lives.
- The caveats matter: this was one survey, in one cancer type, with 119 respondents, run by a Harris Poll for a drug company (Eisai) with advocacy partners — the percentages are a directional signal, not precise measurements for every patient. But the direction is unmistakable.
- Burden is not a reason to refuse treatment that can help. It is a reason to plan for the whole weight of treatment — side effects, time, and home life — and to treat supportive care as half the treatment, not an extra.
The goal is not just to treat the disease. It is to treat the whole person carrying it.
Frequently Asked Questions
What did the ESMO 2026 chemotherapy burden survey find?
It found that 70% of 119 surveyed U.S. endometrial cancer patients felt the burden of chemotherapy was almost as much as the burden of the cancer itself. Fatigue (93%), nausea and vomiting (82%), and muscle cramps (76%) were among the most common burdens, and 59% felt unprepared for treatment's impact on their lives.
Who was surveyed?
119 U.S. patients diagnosed with endometrial (uterine) cancer who had received at least one line of chemotherapy. The median age was 59. About 54% had received more than one line of chemotherapy. The online survey was run by The Harris Poll with Eisai Inc. and the patient organizations ECANA, FORCE, and the Foundation for Women's Cancer.
Does this mean chemotherapy is not worth it?
No. Chemotherapy remains a standard and important part of endometrial cancer treatment, and for many patients it offers real benefit. The survey measures the cost of treatment in daily-life terms so that patients and doctors can plan for it, manage it, and weigh it honestly alongside the benefit.
What is "time toxicity" in cancer treatment?
It is the time treatment itself consumes — travel, waiting, labs, infusions, and recovery days. Patients in this survey averaged 5 hours per chemotherapy session, and many said that time made them feel they were missing out on life. Researchers increasingly count time as a real cost of a treatment plan.
Why do so many chemotherapy patients get muscle cramps?
Cramps during chemotherapy often trace back to fluid and electrolyte losses — from vomiting, diarrhea, reduced eating and drinking, and some drugs — which deplete minerals like magnesium and potassium that muscles need to relax. Frequent cramps are worth reporting; they are often correctable.
What can patients do to feel more prepared for chemotherapy?
Ask for the honest day-by-day picture before starting: which days will be hardest, what the anti-nausea plan is for the days after infusion, how much fluid to drink daily, and what supportive-care referrals (nutrition, palliative care, social work) are available from day one. A simple daily tracker for fluids, food, and worst symptom also helps.
What is the difference between treatment burden and side effects?
Side effects are the physical events — nausea, fatigue, hair loss. Treatment burden is the total weight of being treated: the side effects plus the time, mental load, life disruption, and the spillover onto family and caregivers.
Are there alternatives to chemotherapy for endometrial cancer?
For some patients, yes — depending on the cancer's features and stage, options can include immunotherapy, hormonal therapy, targeted drugs, radiation, surgery, or clinical trials. In this survey, 91% of patients wanted to know more about options besides chemotherapy. The right time to ask is before a plan is set, not after it becomes unbearable.
Why did patients say the second round of chemotherapy was worse?
Among patients who had multiple lines of chemotherapy, 41% rated the later treatment worse than the first. Likely reasons include the cumulative wear of earlier treatment, lower physical reserves, and knowing from experience exactly what the hard days feel like.
How can caregivers get support?
About 1 in 5 patients in this survey named the caregiver's burden as one of chemotherapy's biggest drawbacks. Caregivers can ask the care team directly about respite options, support groups, social work referrals, and counseling — caregiver strain is a legitimate care issue, and raising it helps the patient too.
Sources
1 Eisai Inc. — "Survey Findings Presented at ESMO Congress 2026 Highlight How Chemotherapy Can Impact the Daily Lives of Patients Living with Endometrial Cancer," PR Newswire, October 26, 2026. 2 Eisai Inc. — "Eisai Presents Endometrial Cancer Patient Survey Data at SGO 2026," Eisai US Media, April 10, 2026.
For more information on how HuMOLYTE can support your gut health during chemotherapy, visit our product page or consult your health care provider.
This blog was reviewed by Dr. Sourabh Kharait.
Disclaimer: This blog post is for educational purposes only and is not intended as medical advice. Always consult with your healthcare provider before making changes to your treatment plan, hydration strategies, or diet. The information provided is based on general insights and may not apply to individual circumstances.
